Radar · Neurology in Ontario
Best Neurology Companies in Ontario, Canada
The 76 best Neurology companies in Ontario, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ProMIS Neurosciences.
By Rohit KhannaTrends & Stories
76companies tracked
$1Bdisclosed funding
0unicorns
38have raised
FLIAR INTELLIGENCE · NEUROLOGY × ONTARIO
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
104kcombined LinkedIn audience
70%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Neurology companies in Ontario
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | ProMIS Neurosciences Antibody therapeutics and diagnostics for neurodegenerative diseases 37Funding top 10%Patents top 38%Moat top 38%Talent top 38% All 9 signals ▾Fundingtop 10% Patentstop 38% Moattop 38% Talenttop 38% Newstop 42% Innovationtop 47% Globalbottom 48% Techbottom 34% Marketbottom 24% Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $247M | 4 mo ago | 7 | Neil Cashman Co-Founder | Public | 78 patents Therapeutic antibodies targeting misfolded neurodegeneration proteins (TDP-43, α‑synuclein, Aβ, SOD1). | — |
| 2 | Cybin Provider of psychedelic therapeutics for psychiatric disorders 55Funding top 15%Tech top 42%Talent top 45%Moat top 48% All 6 signals ▾Fundingtop 15% Techtop 42% Talenttop 45% Moattop 48% Marketbottom 47% Globalbottom 37% Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 55/100 | $230M | 11 mo ago | 50 | Aaron Bartlone COO | Public | — | — |
| 3 | Transition Therapeutics Small molecule therapeutics for CNS and metabolic diseases. | $113M | 144 mo ago | 18 | — | Acquired | 16 patents Peptide-based VIP therapeutics and vitamin‑B12/IMPDH inhibitor combos for metabolic, cardiac and antiviral diseases | — |
| 4 | Reunion Neuroscience Developer of therapeutics for mental health conditions | $103M | 29 mo ago | 18 | — | Acquired | 12 patents Design of tryptamine prodrugs and benzyltryptamine derivatives for CNS drug delivery | — |
| 5 | Synaptive Medical Planning and imaging solutions for neurosurgery 74Patents top 20%Funding top 23%Product top 25%Moat top 26% All 11 signals ▾Patentstop 20% Fundingtop 23% Producttop 25% Moattop 26% Innovationtop 31% Growthtop 35% Talenttop 38% Techtop 41% Markettop 43% Globaltop 45% Newsbottom 21% Patents: 730 patents matched (strict assignee match) · 264 filings since 2022 vs 378 in 2017-21 Funding: Raised $76.8M across 12 rounds · 12 rounds over 12 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $77M | 11 mo ago | 200 | Cameron Piron Co-Founder | Series C | 730 patents Intraoperative neuroimaging and navigation systems for brain surgery, including MRI hardware and tractography tools. | — |
| 6 | NeurAxon Pharma Developer of NOS inhibiting small molecules for neuropathies | $53M | 137 mo ago | 15 | — | Series B | — | — |
| 7 | BIONIK Provider of assistive and rehabilitation hardware and software solutions | $40M | 109 mo ago | 12 | Michal Prywata Co-Founder | Public | — | — |
| 8 | Tetra Bio-Pharma Developer of natural medicinal plant-based elements for treating multiple diseases 32Funding top 26%Talent bottom 49%Market bottom 41%Tech bottom 38% All 6 signals ▾Fundingtop 26% Talentbottom 49% Marketbottom 41% Techbottom 38% Globalbottom 36% Newsbottom 24% Funding: Raised $37.9M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $38M | 39 mo ago | 33 | Andre Audet Co-Founder | Public | — | — |
| 9 | Cynapsus Therapeutics Developer of treatment for CNS disorders | $25M | 134 mo ago | 30 | — | Acquired | 47 patents Sublingual film formulations for rapid apomorphine delivery in Parkinson's therapy | — |
| 10 | Grey Matter Neurosciences Developer of medical devices for neurological disease treatment | $14M | 17 mo ago | — | Jeffrey Coull Founder & CEO | Seed | — | — |
| 11 | NoNO Developing pharmaceuticals for the treatment of common health disorders, including stroke, traumatic brain… | $10M | 157 mo ago | 43 | Michael Tymianski President and CEO | Series A | 370 patents Neuroprotective peptide therapeutics targeting ischemic injury and reperfusion damage | — |
| 12 | Regen-Bio Manufacturer of multi-target peptide for curing CNS diseases | $9M | 51 mo ago | 11 | Ringo Ye Co-Founder | Series A | — | — |
| 13 | Psyence Developer of psychedelic therapeutics for mental health disorders 45News top 26%Growth top 36%Funding top 40%Global top 41% All 7 signals ▾Newstop 26% Growthtop 36% Fundingtop 40% Globaltop 41% Talenttop 49% Marketbottom 43% Techbottom 36% News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $9M | 12 mo ago | — | Alan Friedman Co-Founder | Public | — | — |
| 14 | Paradox Immunotherapeutics Developer of immunotherapeutics for the treatment of rare diseases | $7M | 15 mo ago | 9 | Yulong Sun Co-Founder | Series A | 5 patents Therapeutic monoclonal antibodies targeting conformational epitopes of lambda immunoglobulin light chains | — |
| 15 | Winterlight Labs AI-powered speech analysis technology to detect cognitive impairments | $6M | 79 mo ago | 48 | Maria Yancheva Co-Founder And Chief Technology Officer | Acquired | 7 patents AI-driven speech analysis for detecting cognitive and neurological disorders | — |
| 16 | DAMONA Pharmaceuticals Developer of therapeutics for the treatment of cognitive dysfunctions | $6M | 44 mo ago | 6 | Etienne Sibille Founder | Seed | — | — |
| 17 | Cyber Kinetics Technology Brain-computer interface for severely paralyzed patients | $4M | 275 mo ago | 36 | — | Deadpooled | — | — |
| 18 | HDAX Developer of small molecule drugs to treat cancer and CNS disorders | $3M | 21 mo ago | 8 | Pimyupa Manaswiyoungkul Co-Founder & COO | Seed | — | — |
| 19 | MyndTec Developer of functional electrical stimulation therapy for upper limb paralysis 11Funding top 34%Moat top 38%Talent bottom 45%Global bottom 40% All 7 signals ▾Fundingtop 34% Moattop 38% Talentbottom 45% Globalbottom 40% Patentsbottom 38% Marketbottom 24% Innovationbottom 19% Funding: Raised $3.2M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 17 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $3M | 4 mo ago | 11 | Milos Popovic Co-founder and Director | Public | 17 patents Implantable neurostimulation devices with wireless data communication for therapeutic electrical stimulation | — |
| 20 | Rapid Dose Therapeutics Developer of drug delivery technologies to treat the elderly, pediatrics, and neurological disorders | $2M | 26 mo ago | 14 | Mark Upsdell CEO | Public | 12 patents Patents concentrated in chemistry & materials | — |
| 21 | Trexo Robotics A battery operated exoskeleton device | $2M | 87 mo ago | 29 | — | Seed | 10 patents Powered lower‑limb orthotic exoskeletons for weight‑bearing mobility assistance | 1 partnership |
| 22 | ClaroNav Developer of medical 3D visualization and surgical navigation solutions | $2M | 76 mo ago | 40 | Doron Dekel Co-Founder & Co-CEO | Series B | 35 patents Dental navigation and robotic-assisted oral surgery systems | — |
| 23 | KalGene Pharmaceuticals Developing therapeutics and companion diagnostics for Cancer and Alzheimer's. | $2M | 53 mo ago | 2 | — | Series A | — | — |
| 24 | Steadiwear Designer & manufacturer of healthcare gloves 29Growth top 35%Moat top 38%Tech top 42%Funding bottom 49% All 10 signals ▾Growthtop 35% Moattop 38% Techtop 42% Fundingbottom 49% Talentbottom 49% Productbottom 47% Innovationbottom 40% Globalbottom 39% Patentsbottom 37% Marketbottom 17% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $1M | 8 mo ago | 6 | Mark Elias Co-Founder & CEO | Seed | 8 patents Wearable tremor‑damping devices for involuntary hand motion control | — |
| 25 | IRegained Developer of therapeutic solutions for treating stroke or traumatic brain injury | $779K | 50 mo ago | 16 | Vineet Johnson Founder | Seed | 6 patents Indirect movement feedback systems for sensorimotor rehabilitation and therapeutic exercise devices. | 1 partnership |
| 26 | Quantum Biopharma Developer of therapies for neurodegenerative and neuropsychiatric diseases | $500K | 7 mo ago | — | Anthony Durkacz Co-Founder | Public | — | 1 launch |
| 27 | Neural Therapeutics Developer of ethnobotanical drug for neurological disorder | $495K | 15 mo ago | 2 | Ian Campbell Chief Executive Officer | Public | — | — |
| 28 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 35 mo ago | — | Paul Slyke Co-Founder & CSO | Acqui-Hired | — | — |
| 29 | NeuroQore Develops a monophasic repetitive transcranial magnetic stimulation (rTMS) system | $250K | 11 mo ago | 2 | — | Series A | — | — |
Top 12 Neurology companies in Ontario
#1
Public · Toronto, Ontario · founded 2004 · 7 employees$247.3Mraised▾
Public · Toronto, Ontario · founded 2004 · 7 employees
ProMIS Neurosciences discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company utilizes its computational discovery platform, ProMIS, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. It owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 10%Patents
top 38%Moat
top 38%Talent
top 38%News
top 42%Innovation
top 47%Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) · Last round Post IPO (Jan 2026)
Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 78 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Jan 2026Post IPO$175M
- Jul 2025Post IPO$9.2M
- Sep 2023Post IPO$14.9M
- Oct 2022Post IPO$7.5M
Founders & team
Investors
The Kraft Group, Nosterra, Ally Bridge Group, Janus Henderson Investors, Deep Track Capital, Great Point Partners
Tech stack
Apache Http ServerBootstrapFancyboxGodaddyGoogle AnalyticsHcaptcha
#2
Public · Toronto, Ontario · founded 2002 · 50 employees$229.7Mraised▾
Public · Toronto, Ontario · founded 2002 · 50 employees
Provider of psychedelic therapeutics for psychiatric disorders. The product pipeline includes CYB003 a deuterated psilocin for the adjunctive treatment of major depressive disorderCYB004 deuterated dimethyltryptamine compound targeting generalized anxiety disorder and CYB005 aphenethylamine derivative treating neuroinflammation.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 15%Tech
top 42%Talent
top 45%Moat
top 48%Market
bottom 47%Global
bottom 37%Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Post IPO (Jun 2025)
Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Talent: 2 named leaders on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 31k LinkedIn followers — 30.1% of this cohort's audience
Funding rounds
- Jun 2025Post IPO$50M
- Mar 2024Post IPO$150M
- Mar 2022Post IPO$317.1K
- Feb 2021Post IPO—
Founders & team
Investors
Deep Track Capital, Hightrailcapital, Noetic Psychedelic Fund, JLS Fund, Innovating Capital, The Conscious Fund
#3
Series C · Mississauga, Ontario · founded 2012 · 200 employees$76.8Mraised▾
Series C · Mississauga, Ontario · founded 2012 · 200 employees
Synaptive Medical develops planning tools and imaging solutions for application in minimally invasive neurosurgery. Its solutions include BrightMatter Prime which enables thorough and systematic pre-operative preparation with training tools, high fidelity images as well as a smooth and seamless workflow into the surgical suite; and BrightMatter™ Servo which unites high-resolution imaging capabilities with hands-free alignment while seamlessly delivering 3D tractography visualization for navigation into the surgical suite. The company acquired FDA clearance for its product BrightMatter Guide which is a 3D neuro-navigation system.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Patents
top 20%Funding
top 23%Product
top 25%Moat
top 26%Innovation
top 31%Growth
top 35%Patents: 730 patents matched (strict assignee match) · 264 filings since 2022 vs 378 in 2017-21 · Latest publication 2026
Funding: Raised $76.8M across 12 rounds · 12 rounds over 12 yrs (1.0/yr) · Last round Series C (Jul 2025)
Product: 11 distinct product lines · Company stage: Series C
Audience (LinkedIn): 31k LinkedIn followers — 30.1% of this cohort's audience
Funding rounds
- Jul 2025Series C—
- Mar 2023Conventional Debt$40M
- Oct 2020Series C$17M
- Dec 2019Series C$25M
Founders & team
Investors
Linamar, Export Development Canada, General Atlantic, Sensegain Capital, Sissel Technology Development, Espresso Capital
Tech stack
Apple Icloud MailBootstrapCdnjsCloudflareDropboxGoogle Tag Manager
#4
Public · Mississauga, Ontario · founded 2008 · 11 employees$3.2Mraised▾
Public · Mississauga, Ontario · founded 2008 · 11 employees
Developer of functional electrical stimulation therapy for upper limb paralysis. The company has developed a therapy called MyndMove based on the concepts of promoting neuroplasticity to improve the voluntary movement of the hand and arm. MyndMove can be used to treat upper extremity paralysis or paresis post-stroke, spinal cord or traumatic brain injury.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 34%Moat
top 38%Talent
bottom 45%Global
bottom 40%Patents
bottom 38%Market
bottom 24%Funding: Raised $3.2M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) · Last round Post IPO (Feb 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 17 patents
Talent: 1 named leader on record
Funding rounds
- Feb 2026Post IPO$95K
- Jan 2026Post IPO$90K
- Dec 2025Post IPO$80K
- Oct 2025Post IPO$37.5K
Founders & team
Investors
TiE Toronto, HTX, FedDev Ontario, Ontario Centre of Innovation, Springboard Enterprises
#5
Public · Toronto, Ontario · founded 1997$8.6Mraised▾
Public · Toronto, Ontario · founded 1997
Developer of psychedelic therapeutics for mental health disorders. The company's psilocybin drug candidates reduce the symptoms of psychological trauma, PTSD, depression, anxiety, stress, and addiction.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
News
top 26%Growth
top 36%Funding
top 40%Global
top 41%Talent
top 49%Market
bottom 43%News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding: Raised $8.6M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) · Last round Post IPO (Jun 2025)
Audience (LinkedIn): 2k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- Jun 2025Post IPO$441.1K
- Dec 2024Post IPO$2M
- Aug 2023Post IPO$93.5K
- Apr 2023Post IPO$2.2M
Founders & team
Tech stack
Apache Http ServerBootstrapContact Form 7GodaddyGoogle AnalyticsGoogle Font Api
#6
Seed · Toronto, Ontario · founded 2021$14Mraised▾
Seed · Toronto, Ontario · founded 2021
Developer of medical devices for neurological disease treatment. It offers ultrasound headset that facilitate therapeutic brain stimulation for thw treatment of Alzheimer's and other brain diseases and disorders.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public) · hiring: Full-Stack Developer, Software Test Specialist
Activity: 1 awards announced in 12 mo
Funding rounds
- Jan 2025Seed$14M
Founders & team
Investors
Wittington Ventures, TIAP, Ontario Brain Institute, Ontario Centre of Innovation
Tech stack
Core-JsElementorFont AwesomeGoogle AnalyticsHello ElementorHsts
#7
Seed · Toronto, Ontario · founded 2015 · 6 employees$1.3Mraised▾
Seed · Toronto, Ontario · founded 2015 · 6 employees
Designer & manufacturer of healthcare gloves. The company claims that its products are designed to intelligently stabilize the wrist joint in Essential Tremor and Parkinson's disease. It allows patients to perform daily activities comfortably. Its gloves are washable and battery-free.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Growth
top 35%Moat
top 38%Tech
top 42%Funding
bottom 49%Talent
bottom 49%Product
bottom 47%Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents
Tech: 39 technologies across 4/8 capability areas · Cloud: Cloudflare · Observability: Microsoft Clarity, Sentry
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Sep 2025Grant (prize money)—
- Sep 2025Seed—
- Sep 2025Conventional Debt—
- Jul 2021Seed$884.3K
Founders & team
Investors
Ontario Brain Institute, MassChallenge, 3W Partners, CABHI, HaloHealth, Birdhouse
Tech stack
AffirmApple PayAvada Boost SalesCloudflareCloudflare Bot ManagementCore-Js
#8
Series A · Toronto, Ontario · founded 2019 · 9 employees$7Mraised▾
Series A · Toronto, Ontario · founded 2019 · 9 employees
Developer of immunotherapeutics for the treatment of rare diseases. The company has a drug design platform to develop monoclonal antibody (mAb) treatment for protein misfolding diseases. The drug pipeline inlcudes LX-96 for heart failure, KX-99 for ALECT2 amyloidosis, and NX-86 for neurodegenerative diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Feb 2025Series A$7M
Founders & team
Investors
SymBiosis, Springboard Enterprises, Beresford Ventures
#9
Public · Toronto, Ontario · founded 2020$500Kraised▾
Public · Toronto, Ontario · founded 2020
Developer of therapies for neurodegenerative and neuropsychiatric diseases. It offers myelin repairing compounds which include Lucid-MS a patented neuroprotective compound that prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 2.5% of this cohort's audience
Activity: 1 product launches announced in 12 mo
Funding rounds
- Nov 2025Post IPO—
- Dec 2024Post IPO$500K
Founders & team
Tech stack
AccessibeCloudflareDudaHstsJqueryJquery Migrate
#10
Acquired · Toronto, Ontario · founded 2022 · 18 employees$103Mraised▾
Acquired · Toronto, Ontario · founded 2022 · 18 employees
Developer of therapeutics for mental health conditions. The company's product include RE-104 serotonergic psychedelic formulated as a serotonin-2A agonist prodrug for treatment-resistant depression and postpartum depression. also, developing RE-200 series drugs that have selective and specific serotonergic psychedelic candidates.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 3.8% of this cohort's audience · 85 engagements/post (5.7× cohort median)
Funding rounds
- Jan 2024Series A$119.8M
Investors
Novo Holdings, Arkin Holdings, Mitsui Global Investment, Plaisance Capital, FemHealthVentures, Palo Santo
Tech stack
Apache Http ServerBootstrapDocusignFont AwesomeGoogle AnalyticsGoogle Font Api
#11
Seed · Mississauga, Ontario · founded 2021 · 8 employees$3.2Mraised▾
Seed · Mississauga, Ontario · founded 2021 · 8 employees
Developer of small molecule drugs to treat cancer and CNS disorders. The company is developing epigenetic medicines targeting HDAC proteins. The company's product includes HDAC6 inhibitors that help in the selective inhibition of disease-relevant HDAC isoforms.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 4.0% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Sep 2024Seed$3.2M
Founders & team
Investors
SeedFolio, FACIT, TIAP, Eos, Ontario Centre of Innovation, UTEST
Tech stack
Anime.JsCdnjsCloudflareCloudflare Bot ManagementCore-JsElementor
#12
Series A · Ottawa, Ontario · founded 2012 · 2 employees$250Kraised▾
Series A · Ottawa, Ontario · founded 2012 · 2 employees
NeuroQore develops a monophasic repetitive transcranial magnetic stimulation (rTMS) system for treatment-resistant depression. It includes a semiconductor switch that emits a novel magnetic pulse. The device is undergoing clinical trials for Major Depressive Disorder as of February 2017. The device has received approval in Canada.
Funding rounds
- Jul 2025Series A$1.5M
- Oct 2016Seed$250K
Investors
IndieBio, Ontario Brain Institute, SOSV
Funding & investor landscape
$1Btotal disclosed funding
33companies funded
153disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Neil Cashman
Co-Founder · ProMIS Neurosciences
Elliot Goldstein Md
President & CEO · ProMIS Neurosciences
Aaron Bartlone
COO · Cybin
Sarah Hamilton
Director Financial Operations & Strategic Operations · Cybin
Cameron Piron
Co-Founder · Synaptive Medical
Wes Hodges
Co-Founder · Synaptive Medical
Milos Popovic
Co-founder and Director · MyndTec
Alan Friedman
Co-Founder · Psyence
Jeffrey Coull
Founder & CEO · Grey Matter Neurosciences
Mark Elias
Co-Founder & CEO · Steadiwear
Yulong Sun
Co-Founder · Paradox Immunotherapeutics
Anthony Durkacz
Co-Founder · Quantum Biopharma
Prism market signals · Canada · country-scoped Prism corpus, 8,178,667 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN ONTARIO · Health & Bio
How research on Neurotech in Ontario is moving
A read on the academic research around Neurotech in Ontario — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 103 papers.
103 papers · stance +0.31 · 14% breakthrough · 24% concern
top institutions
- Ontario Brain Institute94
- Public Health Ontario4
- Ontario Shores Centre for Mental Health Sciences3
- Children\'s Hospital of Eastern Ontario3
- Ontario Tech University1
leading researchers
Alfonso Fasano · Jürgen Germann · Alexandre Boutet · Gavin J.B. Elias · Srdjan Sumarac · Andrés M. Lozano
prism intelligence · tone & topics
86% positive · 4% critical tone
HealthMedical ResearchNeuroscienceHealthcareMedicineMental Health
▲
Breakthroughs12 · 12%
▲ 0%→13% share
0 median citations92% since 2021mostly methods-led
Breakthroughs are rising (0%→13% of field), led by Deep brain stimulation.
rising sub-themes (early→recent)
- Deep brain stimulation8
- Subthalamic nucleus3
- Stimulation3
- Neuroscience3
- Neuromodulation2
Newly emergingDeep brain stimulation 0→7
Landmark Neural signatures of indirect pathway activity during subthalamic stimulation in Parkinson’s disease · 34 cites
◆
Advancements53 · 51%
▲ 0%→48% share
7 median citations75% since 2021mostly empirical
Advancements are rising (0%→48% of field), led by Deep brain stimulation.
rising sub-themes (early→recent)
- Deep brain stimulation1→34
- Neuroscience1→16
Newly emergingStimulation 0→14 · Subthalamic nucleus 0→12 · Parkinson's disease 0→7
Landmark Predicting optimal deep brain stimulation parameters for Parkinson’s disease using functional MRI and machine learning · 285 cites
▼
Concerns20 · 19%
▲ 0%→20% share
4 median citations85% since 2021mostly empirical
Concerns are rising (0%→20% of field), led by Deep brain stimulation.
rising sub-themes (early→recent)
- Deep brain stimulation1→16
- Parkinson's disease1→6
Newly emergingDystonia 0→8 · Stimulation 0→4 · Subthalamic nucleus 0→3
Landmark Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Behavioural Therapy, Deep Brain Stimulation, and · 155 cites
Common questions
How many Neurology companies are there in Ontario, Canada?
Radar tracks 76 indexable Neurology companies headquartered in Ontario, Canada that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in Ontario, Canada?
The Neurology companies in Ontario, Canada on this list have raised a combined $1B in disclosed equity funding across 33 funded companies.
Which is the highest-funded Neurology company in Ontario, Canada?
ProMIS Neurosciences is the highest-funded Neurology company in Ontario, Canada, with $247.3M in disclosed equity funding.
How many Neurology companies in Ontario, Canada are funded?
33 of the 76 Neurology companies in Ontario, Canada on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in Ontario, Canada?
None of the Neurology companies in Ontario, Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Ontario, Canada Neurology companies?
The most active investors in Ontario, Canada Neurology companies on this list include Ontario Brain Institute, Ontario Centre of Innovation, JLABS, TIAP, BDC.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.